Mazdutide and Tirzepatide: How These Dual Pathway Weight Loss Drugs Really Compare Peptides Unleashed In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the Cagrilintide is a long acting amylin analog that regulates appetite, gastric emptying, and glucagon secretion to treat obesity and related metabolic disorders. There are 2 pathways cagrilintide works: #1 is the Amylin pathway Cagrilintide used for the treatment of obesity and type 2 diabetes Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY 2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity Cagrilintide 10mg 10 Vial Box (100mg Total) $580.0 Edge Peptides